安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like . . .
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1RA) in healthy participants This was a double-blind, placebo-controlled, Phase 1 study
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon . . . - PubMed
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants Diabetes Obes Metab 2023 Sep;25 (9):2634-2641 doi: 10 1111 dom 15184 Epub 2023 Jun 21
- Orforglipron (LY3502970), a novel, oral. . . : Diabetes, Obesity and . . .
Orforglipron is among the first of a new generation of chemically synthesized, non‐peptide GLP‐1RAs that feature oral bioavailability without the need of co‐formulations containing complex absorption enhancing agents
- Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like . . .
DOI: 10 1111 dom 15184 Corpus ID: 259221510 Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants E Pratt, Xiaosu Ma, +5 authors C Benson
- Orforglipron (LY3502970), a novel, oral non-peptide . . . - Europe PMC
Orforglipron had a pharmacodynamic and safety profile similar to that of injectable GLP-1RAs, which supports continued clinical development Read article at publisher's site: https: doi org 10 1111 dom 15184
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon . . . - PubMed
Aim: To report the results of a Phase 1b trial evaluating the safety, pharmacokinetics and pharmacodynamics of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D)
- Effect of Food Consumption on the Pharmacokinetics, Safety, and . . .
We assessed the effect of the prandial state on the pharmacokinetics, safety, and tolerability of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA), in two studies (A and B)
- Orforglipron ( lt;fc gt;LY3502970 lt; fc gt;), a novel, oral nonâ peptide glucagonâ . . .
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become established as a leading class of type 2 diabetes (T2D) and chronic weight management medications 1,2 Currently available GLP-1RAs improve glycaemic control, reduce body weight, and have cardiovascular (CV) benefits in people with T2D 3 However, these drugs are peptide-based and ar
|
|
|